Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: A wisconsin oncology network study

Clinical Breast Cancer

Volumn 14, Issue 3, 2014, Pages 205-211

  Burkard, Mark E ^a,b   Wisinski, Kari B ^a,b   Njiaju, Uchenna O ^a,b   Donohue, Sarahmaria ^a   Hegeman, Robert ^a,b   Stella, Amy ^a,b   Mansky, Patrick ^c   Shah, Varsha ^d   Goggins, Timothy ^e   Qamar, Rubina ^f   Dietrich, Leah ^g   Kim, Kyungmann ^a,b   Traynor, Anne M ^a,b   Tevaarwerk, Amye J ^a,b  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c Bellin Health   (United States)

^d Medical College of Wisconsin   (United States)

^e Fox Valley Hematology Oncology Associates   (United States)

^f Aurora Cancer Care   (United States)

^g GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Febrile neutropenia; Granulocyte colony stimulating factor; Palmar plantar erythrodysthesia; Pegfilgrastim

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRASTUZUMAB; ANTINEOPLASTIC AGENT; TAXOID;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ANOREXIA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; DEHYDRATION; DIARRHEA; DIVERTICULITIS; DOSE DENSIFICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; DYSGEUSIA; DYSPNEA; EARLY CANCER; EXTRAVASATION; FAINTNESS; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; GASTRITIS; HAND FOOT SYNDROME; HEALTH CARE QUALITY; HUMAN; INFECTION; MASTECTOMY; MOTOR NEUROPATHY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; PAIN; PARTIAL MASTECTOMY; PHASE 2 CLINICAL TRIAL; SENSORY NEUROPATHY; SINUS CONGESTION; STOMATITIS; SUICIDAL IDEATION; TREATMENT INDICATION; TREATMENT PLANNING; TRIPLE NEGATIVE BREAST CANCER; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CLINICAL TRIAL; MIDDLE AGED; PROCEDURES;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; FEASIBILITY STUDIES; FEMALE; HUMANS; MIDDLE AGED; TAXOIDS;

EID: 84899983907     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2013.10.018     Document Type: Article

References (25)

1. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group Lancet 352 1998 930 942
2. G. Bonadonna, M. Zambetti, and P. Valagussa Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results JAMA 273 1995 542 547
3. I.C. Henderson, D.A. Berry, and G.D. Demetri et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol 21 2003 976 983
4. M. Martin, T. Pienkowski, and J. Mackey et al. Adjuvant docetaxel for node-positive breast cancer N Engl J Med 352 2005 2302 2313
5. D.A. Berry, N.T. Ueno, and M.M. Johnson et al. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials J Clin Oncol 29 2011 3214 3223
6. L. Norton Evolving concepts in the systemic drug therapy of breast cancer Semin Oncol 24 suppl 10 1997 S10-13-S10-10
7. K. Welte, E. Platzer, and L. Lu et al. Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor Proc Natl Acad Sci U S A 82 1985 1526 1530
8. S. Nagata, M. Tsuchiya, and S. Asano et al. Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor Nature 319 1986 415 418
9. L. Norton Adjuvant breast cancer therapy: current status and future strategies-growth kinetics and the improved drug therapy of breast cancer Semin Oncol 26 1999 1 4
10. M.L. Citron, D.A. Berry, and C. Cirrincione et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 J Clin Oncol 21 2003 1431 1439
11. M. Venturini, L. Del Mastro, and E. Aitini et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial J Natl Cancer Inst 97 2005 1724 1733
12. D. Cameron, P. Barrett-Lee, and P. Canney et al. The UK TACT2 trial: comparison of standard vs accelerated epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019) Cancer Res 72 2012 S3
13. S.E. Jones, M.A. Savin, and F.A. Holmes et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer J Clin Oncol 24 2006 5381 5387
14. S. Jones, F.A. Holmes, and J. O'Shaughnessy et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735 J Clin Oncol 27 2009 1177 1183
15. ClinicalTrials.gov. NSABP B-49: docetaxel and cyclophosphamide compared to anthracycline-based chemotherapy in treating women with HER2-negative breast cancer. Available at: http://clinicaltrials.gov/show/NCT01547741. Accessed: November 19, 2013.
16. D. Takabatake, N. Taira, and F. Hara et al. Feasibility study of docetaxel with cyclophosphamide as adjuvant chemotherapy for Japanese breast cancer patients Japan J Clin Oncol 39 2009 478 483
17. D. Soong, R. Haj, and M.G. Leung et al. High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide J Clin Oncol 27 2009 e101 e102
18. A. Chan, W.H. Fu, V. Shih, J.C. Coyuco, S.H. Tan, and R. Ng Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy Support Care Cancer 19 2011 497 504
19. K. Kawaguchi, H. Ishiguro, and S. Morita et al. Correlation between docetaxel-induced skin toxicity and the use of steroids and H(2) blockers: a multi-institution survey Breast Cancer Res Treat 130 2011 627 634
20. S. Puhalla, E. Mrozek, and D. Young et al. Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer J Clin Oncol 26 2008 1691 1697
21. A. Bardia, C.L. Loprinzi, and M.P. Goetz Hand-foot syndrome after dose-dense adjuvant chemotherapy for breast cancer: a case series J Clin Oncol 24 2006 e18 e19
22. G. Tancini, G. Bonadonna, P. Valagussa, S. Marchini, and U. Veronesi Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles J Clin Oncol 1 1983 2 10
23. Group IBCS Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients J Clin Oncol 14 1996 1885 1894
24. P. Liubao, W. Xiaomin, and T. Chongqing et al. Cost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: doxorubicin plus cyclophosphamide versus docetaxel plus cyclophosphamide Pharmacoeconomics 27 2009 873 886
25. T. Younis, D. Rayson, and C. Skedgel The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer Curr Oncol 18 2011 e288 e296